Interchangeable Biosimilar Now on Express Scripts® Formulary Interchangeable Biosimilar Now on Express Scripts® Formulary Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Low-WAC interchangeable biosimilar is now available Low-WAC interchangeable biosimilar is now available Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate) New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate) New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S. Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S. Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
New agreement with Quallent expands biosimilar access New agreement with Quallent expands biosimilar access Boehringer Ingelheim enters private label agreement for biosimilar
FDA approves additional formulation of biosimilar FDA approves additional formulation of biosimilar US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
New affordability initiative with GoodRx for our biosimilar New affordability initiative with GoodRx for our biosimilar Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar